Perigon Wealth Management LLC increased its holdings in ARK Genomic Revolution ETF (BATS:ARKG – Free Report) by 11.5% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 15,536 shares of the company’s stock after buying an additional 1,608 shares during the quarter. Perigon Wealth Management LLC’s holdings in ARK Genomic Revolution ETF were worth $467,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of ARKG. Marquette Asset Management LLC increased its holdings in ARK Genomic Revolution ETF by 608.3% in the 1st quarter. Marquette Asset Management LLC now owns 850 shares of the company’s stock worth $26,000 after buying an additional 730 shares in the last quarter. VitalStone Financial LLC bought a new stake in shares of ARK Genomic Revolution ETF during the 4th quarter valued at about $37,000. High Net Worth Advisory Group LLC grew its stake in shares of ARK Genomic Revolution ETF by 80.9% during the 1st quarter. High Net Worth Advisory Group LLC now owns 1,118 shares of the company’s stock valued at $51,000 after purchasing an additional 500 shares during the period. Headlands Technologies LLC bought a new stake in shares of ARK Genomic Revolution ETF during the 1st quarter valued at about $110,000. Finally, Avondale Wealth Management grew its stake in shares of ARK Genomic Revolution ETF by 21.4% during the 1st quarter. Avondale Wealth Management now owns 5,673 shares of the company’s stock valued at $171,000 after purchasing an additional 1,000 shares during the period.
ARK Genomic Revolution ETF Stock Up 3.2 %
ARK Genomic Revolution ETF stock opened at $37.29 on Monday. The company’s 50-day moving average price is $34.34 and its 200-day moving average price is $31.31.
ARK Genomic Revolution ETF Company Profile
The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.
Further Reading
- Five stocks we like better than ARK Genomic Revolution ETF
- What Are Dividends? Buy the Best Dividend Stocks
- Stepping Up: Skechers’ Strong Q2 Boosts Investor Confidence
- Quiet Period Expirations Explained
- Should a Lack of Windfall Profits Keep You Out on Chevron Stock?
- How to Invest in Solar Energy
- Two Foolproof Plays for Apple’s Earnings
Want to see what other hedge funds are holding ARKG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARK Genomic Revolution ETF (BATS:ARKG – Free Report).
Receive News & Ratings for ARK Genomic Revolution ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARK Genomic Revolution ETF and related companies with MarketBeat.com's FREE daily email newsletter.
